Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean

Dr. Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PPPaul Ștefan Panaitescu
Paul Ștefan Panaitescu
VRVlad Răzniceanu
Vlad Răzniceanu
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
VNVlad Sever Neculicioiu
Vlad Sever Neculicioiu
HDHanna-Maria Dragoș
Hanna-Maria Dragoș
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
Gut microbiome-targeted interventions such as fecal transplant, prebiotics, probiotics, synbiotics, and antibiotic gut depletion are speculated to be of potential use in delaying the onset and progression of Parkinson’s disease by rebalancing the gut microbiome in the context of the gut–brain axis. Our study aims to organize recent findings regarding these interventions in Parkinson’s disease animal models to identify how they affect neuroinflammation and motor outcomes. A systematic literature search was applied in PubMed, Web of Science, Embase, and SCOPUS for gut microbiome-targeted non-dietary interventions. Studies that investigated gut-targeted interventions by using in vivo murine PD models to follow dopaminergic cell loss, motor tests, and neuroinflammatory markers as outcomes were considered to be eligible. A total of 1335 studies were identified in the databases, out of which 29 were found to be eligible. A narrative systematization of the resulting data was performed, and the effect direction for the outcomes was represented. Quality assessment using the SYRCLE risk of bias tool was also performed. Out of the 29 eligible studies, we found that a significant majority report that the intervention reduced the dopaminergic cell loss (82.76%, 95% CI [64.23%, 94.15%]) produced by the induction of the disease model. Also, most studies reported a reduction in microglial (87.5%, 95% CI [61.65%, 98.45%]) and astrocytic activation (84,62%, 95% CI [54.55%, 98.08%]) caused by the induction of the disease model. These results were also mirrored in the majority (96.4% 95% CI [81.65%, 99.91%]) of the studies reporting an increase in performance in behavioral motor tests. A significant limitation of the study was that insufficient information was found in the studies to assess specific causes of the risk of bias. These results show that non-dietary gut microbiome-targeted interventions can improve neuroinflammatory and motor outcomes in acute Parkinson’s disease animal models. Further studies are needed to clarify if these benefits transfer to the long-term pathogenesis of the disease, which is not yet fully understood. The study had no funding source, and the protocol was registered in the PROSPERO database with the ID number CRD42023461495.

23 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
VRVlad Răzniceanu
Vlad Răzniceanu
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
SPSebastian Romeo Pintilie
Sebastian Romeo Pintilie
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) represent the most aggressive thyroid malignancies, characterized by rapid progression, therapeutic resistance, and poor prognosis. Conventional treatments remain largely ineffective, highlighting the need for novel therapies. Metabolic reprogramming, particularly the Warburg effect (WE), has emerged as a potential therapeutic target. This review synthesizes current evidence on the role of WE in ATC and PDTC, integrating data from molecular profiling, preclinical studies, and emerging therapeutic strategies. Oncogenic alterations frequently observed in ATC and PDTC, including mutations in BRAF, RAS, TP53, and activation of PI3K/AKT/mTOR and HIF-1α signaling, converge to promote glycolytic reprogramming. This metabolic shift supports tumor proliferation, immune evasion, and metastasis through increased glucose uptake, lactate production, and microenvironmental remodeling. Key metabolic nodes, including glucose transporters, hexokinase, and monocarboxylate transporters, are regarded as promising targets. Preclinical studies demonstrate that pharmacological inhibition of these pathways reduces tumor growth, enhances radiosensitivity, and improves response to targeted therapies. Future efforts should focus on combination therapies, biomarker-driven patient stratification, and the development of targeted delivery systems to overcome toxicity and resistance. A deeper understanding of tumor metabolic heterogeneity will be essential for translating these approaches into clinical practice.

1 January 2026 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
VRVlad Răzniceanu
Vlad Răzniceanu
SPSebastian Romeo Pintilie
Sebastian Romeo Pintilie
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Alzheimer’s disease (AD) is responsible for 70% of dementia cases worldwide, with tau hyperphosphorylation and amyloid-β plaque accumulation representing its core pathological hallmarks. Genetic predisposition, oxidative stress, and neuroinflammation contribute to disease onset and progression. Non-coding ribonucleic acids (ncRNAs) are a class of RNAs which control gene expression and whose dysregulation in AD patients has been linked to amyloid production, neuroinflammation, and mitochondrial dysfunction, which ranges from impaired energy metabolism to disrupted mitochondrial biogenesis and dynamics. Our descriptive systematic review surveyed the involvement of ncRNAs in mitochondrial dysfunction in AD across experimental and clinical literature. We identified multiple microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) that directly regulate mitophagy, mitochondrial biogenesis, mitochondrial autophagic, and apoptotic pathways, mitochondrial dynamics, and protein import mechanisms in AD models. Among the most important candidates demonstrating clinical dysregulation, miR-140 and lncRNA NEAT1 regulate mitophagy, while miR-9, miR-34a, miR-146a, miR-155, and miR-485 are implicated in mitochondrial biogenesis and miR-204 in mitochondrial autophagy. LncRNA BDNF-AS, miR-148a-3p, miR-21-5p, and miR-103a-3p emerged as regulators of the mitochondrial apoptosis pathway with confirmed clinical dysregulation. Multiple ncRNAs control mitochondrial dynamics, of which miR-195, miR-124, and miR-455-3p have also been studied in AD patients. Additionally, several ncRNAs were found to indirectly regulate mitochondrial fission, autophagy, and apoptosis, although the underlying mechanisms require further characterization. Thus, while ncRNA-centered AD research is in its early stages, current mechanistic and translational evidence supports mitochondrially relevant ncRNAs as promising candidates for biomarker and therapeutic development.

Verified
Journal Article
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
VRVlad Răzniceanu
Vlad Răzniceanu
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
SPSebastian Romeo Pintilie
Sebastian Romeo Pintilie
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Anaplastic thyroid carcinoma (ATC) represents the most aggressive thyroid malignancy, characterized by rapid progression, therapeutic resistance, and poor prognosis. Conventional treatments remain largely ineffective, highlighting the need for novel therapies. Metabolic reprogramming, particularly the Warburg effect (WE), has emerged as a promising area of investigation. This review synthesizes current evidence on the role of WE in ATC and PDTC, integrating data from molecular profiling, preclinical studies, and emerging therapeutic strategies. Oncogenic alterations frequently observed in ATC, including mutations in BRAF, RAS, TP53, and activation of PI3K/AKT/mTOR and HIF-1α signaling, converge to promote glycolytic reprogramming. This metabolic shift supports tumor proliferation, immune evasion, and metastasis through increased glucose uptake, lactate production, and microenvironmental remodeling. Key metabolic nodes, including glucose transporters, hexokinase, and monocarboxylate transporters, are regarded as promising targets. Preclinical studies suggest that pharmacological inhibition of these pathways reduces tumor growth, enhances radiosensitivity, and improves response to targeted therapies. Future efforts should focus on combination therapies, biomarker-driven patient stratification, and the development of targeted delivery systems to overcome toxicity and resistance. A deeper understanding of tumor metabolic heterogeneity will be essential for translating these approaches into clinical practice.